source
- Novo Nordisk files lawsuit against Eli Lilly over allegedly deceptive GLP-1 dose adsNovo Nordisk has initiated legal action against Eli Lilly in a U.S. court, alleging that Lilly's recent advertisements misrepresent the dosing of GLP-1 obesity treatments. The company says the ads…
- Novartis CEO says China partnerships driven by science, not market strategyNovartis chief executive Vas Narasimhan told reporters during the second quarter earnings call that the company’s recent agreements in China are motivated by scientific opportunities rather than a…